FDA approves Journey Medical's drug for long-term skin condition
04/11/2024 12:09
Nov 4 (Reuters) - The U.S. Food and Drug Administration
has approved Journey Medical's DERM.O drug for the treatment
of a long-term skin condition called rosacea, the company said
on Monday.
(Reporting by Sruthi Narasimha Chari, Puyaan Singh and Mariam
Sunny in Bengaluru; editing by Alan Barona and Shilpi Majumdar)
((mailto:SruthiNarasimha.Chari@thomsonreuters.com;
mailto:puyaan.singh@thomsonreuters.com))
Recent news on Journey Medical
See all newsJourney Medical Corp expected to post a loss of 1 cent a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce
U.S. STOCKS ON THE MOVE-Cerebras, Madison Square Garden Sports
U.S. STOCKS ON THE MOVE-Five Below, Salesforce, IBM, Akamai Technologies